Terms: = Bone cancer AND TMPRSS2, PRSS10, 7113, ENSG00000184012, O15393 AND Diagnosis
4 results:
1. Brain metastasis in a patient with BRCA2-mutated treatment-related neuroendocrine prostate carcinoma and long-term response to radiotherapy and Olaparib: A case report and literature review.
Uehara R; Obinata D; Hashimoto S; Nakahara K; Uchida H; Yoshizawa T; Mochida J; Yamaguchi K; Sakaguchi M; Ozawa Y; Mori F; Miura K; Ishige T; Masuda S; Nakayama T; Takahashi S
Medicine (Baltimore); 2024 Mar; 103(9):e37371. PubMed ID: 38428891
[TBL] [Abstract] [Full Text] [Related]
2. Assessing survival outcomes and complication profiles following surgical excision and radiotherapy as interventions for skull base chordoma: a systematic review of operative margins and surgical approaches.
Brown NJ; Gendreau J; Kuo CC; Nguyen O; Yang C; Catapano JS; Lawton MT
J Neurooncol; 2023 Oct; 165(1):41-51. PubMed ID: 37880419
[TBL] [Abstract] [Full Text] [Related]
3. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
[TBL] [Abstract] [Full Text] [Related]
4. Catalytic cleavage of the androgen-regulated tmprss2 protease results in its secretion by prostate and prostate cancer epithelia.
Afar DE; Vivanco I; Hubert RS; Kuo J; Chen E; Saffran DC; Raitano AB; Jakobovits A
Cancer Res; 2001 Feb; 61(4):1686-92. PubMed ID: 11245484
[TBL] [Abstract] [Full Text] [Related]
